Health Trials

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

ConditionsRefractory Rheumatoid Arthritis (RA)Idiopathic Inflammatory Myopathies (IIMs)Systemic Sclerosis (SSc)Rheumatoid Arthritis (RAIIMMyositisSclerodermaSjogren SyndromeSjogrens Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorArtiva Biotherapeutics, Inc.

About this trial

A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.

Eligibility criteria

Qualifiers

Documented diagnosis of RA, meeting the 2010 ACR/EULAR classification criteria.

Rheumatoid Factor (RF) or Anti Citrullinated Protein Antibody (ACPA) positive.

High-sensitivity C-reactive protein (hs-CRP) > 3 mg/L or Erythrocyte Sedimentation Rate (ESR) > 28 mm/hr.

Have had prior treatment for a period of at least 12 weeks with a biologic disease modifying anti-rheumatic drug and were deemed refractory by the treating physician.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Allogeneic NK Cells

Treatment groups

90 Participants
are divided into 1 treatment group

Sponsors and collaborators

Artiva Biotherapeutics, Inc.

Lead sponsor

Source ClinicalTrials.gov